BPC-157 Dosage Chart.

Ten units, if you mixed a 5 mg vial with 2 mL of bacteriostatic water. That gives 2,500 mcg/mL, and one unit on a U-100 syringe is 0.01 mL, so one unit equals 25 mcg. On the same mix, 500 mcg is 20 units and 750 mcg is 30 units. Change either the vial size or the water volume and every one of those numbers changes: a 10 mg vial in the same 2 mL makes each unit 50 mcg, so 250 mcg becomes 5 units, not 10. Always recalculate from the vial in front of you rather than reusing a unit count you read somewhere.

Convention. It does not appear in any controlled human trial, any drug label, or any registered protocol with published results. It propagated out of clinic and vendor protocols and hardened into a standard through repetition, usually expressed as 2–7 mcg per kilogram per day. It is the range most sources converge on, which is a real and useful thing to know; it is just not the same thing as a proven dose.

Yes, but not this way and not in a controlled trial. Searching PubMed for BPC 157 with the clinical-trial filter returns zero results. What exists is three small uncontrolled case series, all from the same group: intra-articular injection into the knee for various knee pain, reported in 2021 with 16 evaluable patients; 10 mg given intravesically into the bladder for interstitial cystitis in 12 patients; and intravenous dosing up to 20 mg in two patients. None were placebo-controlled, none were subcutaneous, and none were large. Separately, one Phase 1 study of oral BPC-157 tablets completed years ago and never posted results, and a Phase 2 trial of subcutaneous BPC-157 for hamstring strain began recruiting in 2026 without disclosing its dose in the registry.

Nobody has compared them in a person, which is worth knowing before you pay a premium for either. The one interesting fact is that the only completed registered human study used oral tablets (1 mg tablets, up to 9 mg a day), so the oral route has more registered human exposure behind it than the subcutaneous route does, even though its results were never published. Oral capsule protocols are conventionally dosed several times higher than injectable ones to account for lower systemic absorption, and gut-focused protocols favour oral specifically because the target tissue is the one the capsule lands in. Arginate-salt versions are marketed as more stable; no published human comparison supports the premium.

Convention says yes and there is no human evidence either way for subcutaneous injection. The preclinical work that built BPC-157 its reputation used a mix of routes, including systemic ones, and often produced effects at sites well away from the injection, which argues the effect is not purely local. Injecting into or immediately around an inflamed joint, a tendon sheath or a suspected tear also carries a real infection risk that an unproven benefit does not offset. The one human case series that did inject directly into a joint was done by a clinician under sterile conditions. Subcutaneous into the abdomen or flank, sites rotated, is the low-risk default.

The working convention is about 28 days refrigerated at 2–8 °C when mixed with bacteriostatic water, which contains a preservative. Plain sterile water has no preservative and should be treated as single-session. Be aware that the 28-day figure is standard peptide-handling practice carried across from other compounds; no published stability study for BPC-157 in solution establishes it. Keep the vial dark, never freeze it after mixing, and discard it if the solution turns cloudy, develops particles, or the cake never dissolved cleanly.

In a tested sport, assume yes. BPC-157 is prohibited at all times under WADA category S0, unapproved substances, and USADA states plainly that it is not approved for human clinical use by any global regulatory authority. There is no therapeutic-use exemption available for a compound with no approved indication, so this is disqualifying regardless of dose or route. A standard workplace or pre-employment drug panel does not look for it.

Because the FDA has said there is no legal basis for compounding pharmacies to use it, which is why compounded BPC-157 largely disappeared from clinics that once offered it. Everything sold now is research-grade material outside that pathway. That is a dosing issue as much as a legal one: research chemicals carry no pharmacopeial requirement for sterility, endotoxin or identity testing, so the number on the label is a claim rather than a specification. Buy from vendors that publish third-party HPLC and mass-spec results for the specific batch you received, and treat an unverified vial as an unknown quantity no matter how carefully you do the arithmetic.